These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34885096)

  • 21. Localized prostate cancer: An analysis of the Centers for Disease Control and Prevention Breast and Prostate Cancer Data Quality and Patterns of Care study (CDC PoC-BP).
    Celtik K; Wallis CJD; Lo M; Lim K; Lipscomb J; Fleming S; Wu XC; Anderson RT; Thompson TD; Farach A; Hamilton AS; Miles BJ; Satkunasivam R
    Can Urol Assoc J; 2022 Jul; 16(7):E391-E398. PubMed ID: 35230935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
    Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
    BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    Liu JM; Liu YP; Chuang HC; Wu CT; Su YL; Hsu RJ
    PLoS One; 2020; 15(2):e0229263. PubMed ID: 32074125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Greenberger BA; Zaorsky NG; Den RB
    Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
    Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
    Yamamoto S; Masuda H; Urakami S; Fujii Y; Sakamoto K; Kozuka T; Oguchi M; Fukui I; Yonese J
    Urology; 2015 Feb; 85(2):407-13. PubMed ID: 25623703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy.
    Shakespeare TP; Chin S; Manuel L; Wen S; Hoffman M; Wilcox SW; Aherne NJ
    J Med Imaging Radiat Oncol; 2017 Feb; 61(1):141-145. PubMed ID: 27531363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 1-Year Hospital Volume on Surgical Margin and Biochemical-Failure-Free Survival in Patients Undergoing Robotic versus Nonrobotic Radical Prostatectomy: A Nationwide Cohort Study from the National Taiwan Cancer Database.
    Chang SC; Hsu CH; Lin YC; Wu SY
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33513885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.
    Thomas HR; Chen MH; D'Amico AV; Bennett CL; Kattan MW; Sartor O; Stein K; Nguyen PL
    Clin Genitourin Cancer; 2018 Aug; 16(4):313-317. PubMed ID: 29866496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Saad A; Goldstein J; Lawrence YR; Spieler B; Leibowitz-Amit R; Berger R; Davidson T; Urban D; Tsang L; Alezra D; Weiss I; Symon Z
    Radiat Oncol; 2017 Jan; 12(1):5. PubMed ID: 28061904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy.
    Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Yu HJ; Lai MK; Liu SP; Pu YS; Cheng JC
    Oncotarget; 2016 Jul; 7(28):44224-44235. PubMed ID: 27317764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis.
    Markovina S; Meeks MW; Badiyan S; Vetter J; Gay HA; Paradis A; Michalski J; Sandhu G
    Adv Radiat Oncol; 2018; 3(2):190-196. PubMed ID: 29904744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE
    PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy.
    Lan K; Zhu J; Zhang J; Zhou S; Yang Y; Feng Z; Zhang L; Wang S; Xi M
    Radiother Oncol; 2020 Aug; 149():228-235. PubMed ID: 32474127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Sundi D; Tosoian JJ; Nyame YA; Alam R; Achim M; Reichard CA; Li J; Wilkins L; Schwen Z; Han M; Davis JW; Klein EA; Schaeffer EM; Stephenson AJ; Ross AE; Chapin BF
    Cancer; 2019 Feb; 125(3):391-397. PubMed ID: 30423193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
    BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.